axsome therapeutics developing novel therapies for cns disorders expanding treatment options to improve the lives of patients living with cns disorders view pipeline axs treatment resistant depression trd trd occurs in individuals suffering from major depression who fail to respond to initial antidepressant treatments axs is a novel oral investigational drug product incorporating multiple mechanisms of action under development for the treatment of trd and alzheimer’s disease agitation learn more about trd and axs axs complex regional pain syndrome crps crps is characterized by excessive lingering pain in one of the limbs usually after an injury trauma or surgery axs is a novel oral nonopioid investigational drug product under development for the treatment of crps and other chronic pain conditions learn more about crps and axs in the news july   axsome therapeutics announces axs moseic™ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial click to view full release july   axsome therapeutics initiates phase  trial of axs for alzheimer’s disease agitation click to view full release july   axsome therapeutics appoints john golubieski as chief financial officer click to view full release see all news knee oa clinical trialcoast study axs is being evaluated in the coast clinical knee osteoarthritis symptom treatment  coast is a phase  multinational multicenter randomized doubleblind placebocontrolled trial designed to evaluate the efficacy and safety of axs for the treatment of the pain of knee oa associated with bmls more information about the study can be found atwwwclinicaltrialsgovtrd clinical trialstride studytrdstudycomaxs is being evaluated in the stride symptom treatment in resistant depression  study stride is a phase  multicenter randomized doubleblind activecontrolled trial designed to evaluate the efficacy and safety of axs in the treatment of treatment resistant depression trd more information about the study can be found atwwwclinicaltrialsgovcrps clinical trialcreate trialcrpstrialcomaxs is being evaluated in the create crps treatment evaluation  study create is a phase  multinational multicenter randomized doubleblind placebocontrolled trial designed to evaluate the efficacy and safety of axs for the treatment of pain associated with complex regional pain syndrome crps more information about the study can be found atwwwclinicaltrialsgov axsome therapeutics management team management team herriot tabuteau mdchief executive officerdr tabuteau has served as our founder chief executive officer and chairman of our board of directors since our founding in january  prior to founding our company dr tabuteau was a senior analyst and partner at healthcosac capital now known as healthcor where he was responsible for the biotechnology genomics and instrumentation portfolios previously dr tabuteau was the healthcare analyst at kingdon capital prior to that position dr tabuteau was a senior research analyst at banc of america securities covering the hospital supplies sector prior to banc of america dr tabuteau was part of the healthcare investment banking group at goldman sachs dr tabuteau earned his md from yale university school of medicine and his bachelor of arts in molecular biology and biochemistry from wesleyan universityrobert niecestro phdvice president clinical and regulatorydr niecestro has served as our head of regulatory since october  in addition since  dr niecestro has served as a consultant to a variety of biopharmaceutical companies including keryx biopharmaceuticals inc and tg therapeutics inc prior to  dr niecestro held numerous senior management positions including serving as vice president of clinical development for andrx laboratories senior director clinical development and therapeutic head for gastrointestinal oncology and stroke at eisai inc and director clinical operations and nda planning for organon inc while at andrx dr niecestro was part of the team that developed the following approved drugs extendedrelease metformin extendedrelease lovastatin and valproic acid at eisai dr niecestro played a pivotal role in the development and commercialization of aciphex rabeprazole sodium and the postnda program for aricept donepezil sodium and was involved in the launch of both the oncology and neurology franchises in the united states while at organon dr niecestro was part of the team that developed and commercialized the following drugs zemuron rocuronium bromide orgaran danaparoid sodium humegon fshlh follistim recombinant fsh beta and mircette desogestrelethinyl estradiol and ethinyl estradiol dr niecestro has been involved in the filing of over  inds has over  peerreviewed publications and holds  patents dr niecestro completed his graduate and postgraduate work at the university of illinois at chicagoconnie amesvice president financems ames has served as our vice president finance since february  ms ames joined us from keryx biopharmaceuticals inc which she joined in  where she served most recently as senior director finance and accounting during her tenure there ms ames played a critical role in growing the finance and accounting department through keryx’s transition from a developmentstage company to a fully integrated commercial organization she was also responsible for leading keryx’s compliance with securities and exchange commission rules and regulations prior to joining keryx she was with deloitte and touche llp independent certified public accountants where she served as a senior associate ms ames received a bachelor of science in accounting from ithaca college and is a member of the american institute of certified public accountantsmark jacobsonvice president operationsmr jacobson has served as our vice president operations since october  and as our senior director of operations from april  until october  prior to joining axsome he was director of corporate development at stemline therapeutics inc where he played a critical role in advancing the company from a person team in  to the successful completion of an initial public offering and secondary public offering in  which together raised approximately  million for the company while at stemline mr jacobson’s responsibilities spanned investor relations public relations corporate operations and intellectual property mr jacobson began his career in healthcare communications at publicis healthcare communications group mr jacobson earned a master of arts in biotechnology from columbia university and a bachelor of science in biology from iowa state university axsome therapeutics overview  pipeline overview we aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated medicines that expand the treatment options available to caregivers and improve the lives of patients living with cns disorders axsome therapeutics inc is a clinicalstage biopharmaceutical company developing novel medicines for the management of central nervous system cns disorders by focusing on this therapeutic area we are addressing significant and growing markets where current treatment options are limited or inadequate our pipeline includes two latestage product candidates axs and axs which we are developing for multiple indications pipeline axsome therapeutics is building a portfolio of differentiated product candidates that address unmet medical needs some of our product candidates combine multiple mechanisms of action to produce novel medicines that address deficiencies of current approaches the company’s current pipeline includes two latestage product candidates and one preclinical candidate axs axs is a novel oral investigational drug product under development for the treatment of central nervous system cns disorders axs utilizes axsome’s technology of combining bupropion and dextromethorphan dextromethorphan is an nmda receptor antagonist sigma receptor agonist and inhibitor of the serotonin and norepinephrine transporters bupropion serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor and a nicotinic acetylcholine receptor antagonist we are initially developing axs for the treatment of the following conditions treatment resistant depression trd and agitation in patients with alzheimer’s disease ad axs is an investigational drug product not approved by the fdalearn more about axs and our target indications axs axs disodium zoledronate tetrahydrate is a potentially first in class oral targeted non opioid therapeutic for chronic pain we are initially developing axs for the treatment of pain in the following three conditions complex regional pain syndrome crps knee osteoarthritis oa associated with bone marrow lesions bmls and chronic low back pain clbp associated with modic changes mcs axs has been granted fast track designation by the fda for the treatment of pain associated with crps as well as for the treatment of knee oa associated with bmls axs has also been granted orphan drug designation by the fda and orphan medicinal product designation by the ema for the treatment of crps axs is an investigational product candidate not approved by the fdalearn more about axs and our target indications axsome therapeutics company company posted november   by cognitiondev in the news july   axsome therapeutics announces axs moseic™ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial click to view full release july   axsome therapeutics initiates phase  trial of axs for alzheimer’s disease agitation click to view full release july   axsome therapeutics appoints john golubieski as chief financial officer click to view full release see all news axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets primary endpoint in phase  clinical trial  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    axsome therapeutics inc    axsm axsome therapeutics inc axsm add to my list    mes derni�res consultmost popular manage my lists  delayed     pm  usd    a axsome therapeu  announces axs moseic meloxicam and esomeprazol  axsome therapeutics announces axs moseic™ meloxicam and  axsome therapeu  axsm files an k other events summaryquoteschartsnewsanalysiscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets primary endpoint in phase  clinical trial    am cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields axsome therapeutics inc nasdaqaxsm a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders today announced positive topline clinical trial results from a phase  pharmacokinetic study of axs a novel oral nonopioid fixeddose combination of meloxicam and esomeprazole being developed for the treatment of osteoarthritis and rheumatoid arthritis axsome has received from the us food and drug administration fda preinvestigational new drug application preind written guidance on a proposed clinical developmental plan for axs based on this guidance axsome believes that axs is phase ready axs is now axsomes third product candidate in clinical development and its second differentiated oral nonopioid product candidate for the management of chronic pain the clinical trial results demonstrated for the first time rapid achievement of peak plasma levels of meloxicam after oral administration meloxicam is a longacting nonsteroidal antiinflammatory drug nsaid with cox preferential inhibition and potent pain relieving efficacy however standard meloxicam has an extended time to maximum plasma concentration tmax which delays its onset of action axs utilizes axsomes proprietary moseic molecular solubility enhanced inclusion complex technology to substantially increase the solubility and speed the absorption of meloxicam while maintaining durability of action axs also incorporates esomeprazole a proton pump inhibitor to reduce the risk of nsaidassociated gastrointestinal ulcers which can occur with chronic nsaid use axs provides the benefits of oral administration and demonstrates a more rapid meloxicam tmax than that reported with intramuscular administration highlighting the potential for faster pain relief in addition axs maintains the long halflife of meloxicam which enables oncedaily dosing and sustained effect said herriot tabuteau md chief executive officer of axsome these results indicate that axs has a potentially bestinclass nsaid profile based on the differentiated pharmacokinetic profile of moseic meloxicam and the potentially enhanced gastrointestinal safety from the esomeprazole component the potential efficacy and safety advantages of axs as compared to currently available nsaids could provide significant benefit to patients the study compared the pharmacokinetics of meloxicam and esomeprazole after oral administration of axs tablets meloxicam  mg esomeprazole  mg and commercially available mobic tablets  mg meloxicam and nexium capsules  mg esomeprazole in healthy volunteers the median tmax for meloxicam the trials primary endpoint was  times faster for axs as compared to mobic  hour versus  hours for axs and mobic respectively pc  tbreak media all rights reserved provided by syndigate media inc syndigateinfo source middle east  north african newspapers  latest news on axsome therapeutics inc a axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets  axsome therapeutics announces axs moseic™ meloxicam and esomeprazol  axsome therapeuticsinc nasdaq  axsm files an k other events  axsome therapeutics inc  other events financial statements and exhibits for  axsome therapeutics initiates phase  trial of axs for alzheimer’s  axsome therapeuticsinc nasdaq  axsm files an k departure of directors or   axsome therapeutics inc  change in directors or principal officers regulatio  axsome therapeutics appoints john golubieski as chief financial officer  axsome therapeutics  appoints myrtle potter to its board of directors  axsome therapeutics inc  change in directors or principal officers regulatio more news news from seekingalpha  midday gainers  losers  healthcare gainers  losers as of    am  stocks to watch next week  an analysis of axsome therapeutics upcoming catalysts  midday gainers  losers financials  sales   ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales   capi  sales  x capitalization  m more financials chart axsome therapeutics inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends axsome therapeutics inc short termmidtermlong termtrendsbullishbullishneutral technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus buy number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitleherriott tabuteau chairman  chief executive officer mark l jacobson secretary  vice presidentoperations constance ames principal financial officer  treasurer roger a jeffs lead independent director mark coleman independent director more about the company sector and competitors st jancapitalization m axsome therapeutics inc amgen  celgene corporation  gilead sciences  regeneron pharmaceuticals  vertex pharmaceuticals  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets primary endpoint in phase  clinical trial  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    axsome therapeutics inc    axsm axsome therapeutics inc axsm add to my list    mes derni�res consultmost popular manage my lists  delayed     pm  usd    a axsome therapeu  announces axs moseic meloxicam and esomeprazol  axsome therapeutics announces axs moseic™ meloxicam and  axsome therapeu  axsm files an k other events summaryquoteschartsnewsanalysiscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets primary endpoint in phase  clinical trial    am cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields axsome therapeutics inc nasdaqaxsm a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders today announced positive topline clinical trial results from a phase  pharmacokinetic study of axs a novel oral nonopioid fixeddose combination of meloxicam and esomeprazole being developed for the treatment of osteoarthritis and rheumatoid arthritis axsome has received from the us food and drug administration fda preinvestigational new drug application preind written guidance on a proposed clinical developmental plan for axs based on this guidance axsome believes that axs is phase ready axs is now axsomes third product candidate in clinical development and its second differentiated oral nonopioid product candidate for the management of chronic pain the clinical trial results demonstrated for the first time rapid achievement of peak plasma levels of meloxicam after oral administration meloxicam is a longacting nonsteroidal antiinflammatory drug nsaid with cox preferential inhibition and potent pain relieving efficacy however standard meloxicam has an extended time to maximum plasma concentration tmax which delays its onset of action axs utilizes axsomes proprietary moseic molecular solubility enhanced inclusion complex technology to substantially increase the solubility and speed the absorption of meloxicam while maintaining durability of action axs also incorporates esomeprazole a proton pump inhibitor to reduce the risk of nsaidassociated gastrointestinal ulcers which can occur with chronic nsaid use axs provides the benefits of oral administration and demonstrates a more rapid meloxicam tmax than that reported with intramuscular administration highlighting the potential for faster pain relief in addition axs maintains the long halflife of meloxicam which enables oncedaily dosing and sustained effect said herriot tabuteau md chief executive officer of axsome these results indicate that axs has a potentially bestinclass nsaid profile based on the differentiated pharmacokinetic profile of moseic meloxicam and the potentially enhanced gastrointestinal safety from the esomeprazole component the potential efficacy and safety advantages of axs as compared to currently available nsaids could provide significant benefit to patients the study compared the pharmacokinetics of meloxicam and esomeprazole after oral administration of axs tablets meloxicam  mg esomeprazole  mg and commercially available mobic tablets  mg meloxicam and nexium capsules  mg esomeprazole in healthy volunteers the median tmax for meloxicam the trials primary endpoint was  times faster for axs as compared to mobic  hour versus  hours for axs and mobic respectively pc  tbreak media all rights reserved provided by syndigate media inc syndigateinfo source middle east  north african newspapers  latest news on axsome therapeutics inc a axsome therapeutics  announces axs moseic meloxicam and esomeprazole meets  axsome therapeutics announces axs moseic™ meloxicam and esomeprazol  axsome therapeuticsinc nasdaq  axsm files an k other events  axsome therapeutics inc  other events financial statements and exhibits for  axsome therapeutics initiates phase  trial of axs for alzheimer’s  axsome therapeuticsinc nasdaq  axsm files an k departure of directors or   axsome therapeutics inc  change in directors or principal officers regulatio  axsome therapeutics appoints john golubieski as chief financial officer  axsome therapeutics  appoints myrtle potter to its board of directors  axsome therapeutics inc  change in directors or principal officers regulatio more news news from seekingalpha  midday gainers  losers  healthcare gainers  losers as of    am  stocks to watch next week  an analysis of axsome therapeutics upcoming catalysts  midday gainers  losers financials  sales   ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales   capi  sales  x capitalization  m more financials chart axsome therapeutics inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends axsome therapeutics inc short termmidtermlong termtrendsbullishbullishneutral technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus buy number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitleherriott tabuteau chairman  chief executive officer mark l jacobson secretary  vice presidentoperations constance ames principal financial officer  treasurer roger a jeffs lead independent director mark coleman independent director more about the company sector and competitors st jancapitalization m axsome therapeutics inc amgen  celgene corporation  gilead sciences  regeneron pharmaceuticals  vertex pharmaceuticals  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave axsome therapeutics announces axs moseic™ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial nasdaqaxsm english français register sign in axsome therapeutics announces axs moseic™ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial july    et  source axsome therapeutics inc axs is an oral rapidlyabsorbed oncedaily nonopioid cox preferential pain therapeutic with a gastroprotectant primary endpoint met with  times faster time to maximum plasma concentration tmax of meloxicam versus mobic® p therapeutic plasma levels of meloxicam achieved within  minutes of oral dosing of axs gastroprotective concentrations of esomeprazole achieved  phase ready based on fda preind guidance axs utilizes axsome’s moseic™ delivery technology axs to complement commercialization of axs in development for complex regional pain syndrome new york july   globe newswire  axsome therapeutics inc nasdaqaxsm a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders today announced positive topline clinical trial results from a phase  pharmacokinetic study of axs a novel oral nonopioid fixeddose combination of meloxicam and esomeprazole being developed for the treatment of osteoarthritis and rheumatoid arthritis axsome has received from the us food and drug administration fda preinvestigational new drug application preind written guidance on a proposed clinical developmental plan for axs based on this guidance axsome believes that axs is phase ready axs is now axsome’s third product candidate in clinical development and its second differentiated oral nonopioid product candidate for the management of chronic pain the clinical trial results demonstrated for the first time rapid achievement of peak plasma levels of meloxicam after oral administration meloxicam is a longacting nonsteroidal antiinflammatory drug nsaid with cox preferential inhibition and potent pain relieving efficacy however standard meloxicam has an extended time to maximum plasma concentration tmax which delays its onset of action axs utilizes axsome’s proprietary moseic™ molecular solubility enhanced inclusion complex technology to substantially increase the solubility and speed the absorption of meloxicam while maintaining durability of action axs also incorporates esomeprazole a proton pump inhibitor to reduce the risk of nsaidassociated gastrointestinal ulcers which can occur with chronic nsaid use “axs provides the benefits of oral administration and demonstrates a more rapid meloxicam tmax than that reported with intramuscular administration highlighting the potential for faster pain relief in addition axs maintains the long halflife of meloxicam which enables oncedaily dosing and sustained effect” said herriot tabuteau md chief executive officer of axsome “these results indicate that axs has a potentially bestinclass nsaid profile based on the differentiated pharmacokinetic profile of moseic™ meloxicam and the potentially enhanced gastrointestinal safety from the esomeprazole component the potential efficacy and safety advantages of axs as compared to currently available nsaids could provide significant benefit to patients” the study compared the pharmacokinetics of meloxicam and esomeprazole after oral administration of axs tablets meloxicam  mg esomeprazole  mg and commercially available mobic® tablets  mg meloxicam and nexium® capsules  mg esomeprazole in healthy volunteers the median tmax for meloxicam the trial’s primary endpoint was  times faster for axs as compared to mobic®  hour versus  hours for axs and mobic respectively p axs also demonstrated higher mean maximum plasma concentration cmax p faster time to therapeutic plasma concentration p and time to halfmaximal plasma concentration p as compared to mobic® terminal halflives for meloxicam were similar for axs and mobic® at approximately  and  hours respectively plasma concentrations and terminal halflives of esomeprazole after axs and nexium® administration were comparable axs was well tolerated with reported adverse events being similar across the three treatment arms there were no serious adverse events in the study “with its differentiated profile and phase ready status axs complements axs which is currently in phase  trials in complex regional pain syndrome and knee osteoarthritis” continued dr tabuteau “the overlapping patient and physician audiences for axs and axs should allow axsome to leverage our commercialization efforts we look forward to the further development of axs and to a data readout for axs in complex regional pain syndrome anticipated in the fourth quarter” phase  trial design the study was a randomized parallel group trial to evaluate the pharmacokinetics and safety of meloxicam and esomeprazole after single and multiple dose administration of axs in healthy volunteers a total of  subjects were randomly assigned in a  ratio to treatment with axs tablets  mg meloxicam  mg esomeprazole mobic® tablets  mg meloxicam or nexium® capsules  mg esomeprazole once daily for  days under fasting conditions the primary endpoint was the tmax of meloxicam secondary endpoints included cmax time to half maximum concentration and time to therapeutic concentration about the nsaid market nonsteroidal antiinflammatory drugs nsaids are widely used for the treatment of pain and arthritis approximately  million prescriptions were written for nsaids overall in the us in  of which approximately  were written for meloxicam chronic use of nsaids has been reported to be associated with the development of gastrointestinal ulcers in as many as  of patients about axs axs is an oral nonopioid fixeddose combination of moseic™ meloxicam and esomeprazole which is being developed for the treatment of chronic pain meloxicam is a longacting nonsteroidal antiinflammatory drug nsaid with cox preferential inhibition and potent painrelieving efficacy axs utilizes axsome’s proprietary moseic™ molecular solubility enhanced inclusion complex technology to substantially increase the solubility and speed the absorption of meloxicam while maintaining durability of action esomeprazole is a proton pump inhibitor which lowers stomach acidity and which has been shown to reduce the occurrence of nsaidinduced gastrointestinal ulcers axs is designed to provide rapid effective pain relief and to reduce the risk of nsaidinduced ulcers with convenient oncedaily dosing about axsome therapeutics inc axsome therapeutics inc is a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders for which there are limited treatment options axsome’s product candidate portfolio includes three clinicalstage candidates axs axs and axs axs is currently in a phase  trial in treatment resistant depression trd and a phase  trial in agitation in patients with alzheimer’s disease ad axs is currently in phase  trials in complex regional pain syndrome crps and knee osteoarthritis oa associated with bone marrow lesions bmls with an additional phase  trial planned in chronic low back pain clbp associated with modic changes mcs a phase  trial of axs has been completed axs axs and axs are investigational drug products not approved by the fda for more information please visit the company website at wwwaxsomecom the company may occasionally disseminate material nonpublic information on the company website forward looking statements certain matters discussed in this press release are “forwardlooking statements” we may in some cases use terms such as “predicts” “believes” “potential” “continue” “estimates” “anticipates” “expects” “plans” “intends” “may” “could” “might” “will” “should” or other words that convey uncertainty of future events or outcomes to identify these forwardlooking statements in particular the company’s statements regarding trends and potential future results are examples of such forwardlooking statements the forwardlooking statements include risks and uncertainties including but not limited to the success timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates including statements regarding the timing of initiation and completion of the trials futility analyses and receipt of interim results the timing of and our ability to obtain and maintain us food and drug administration or other regulatory authority approval of or other action with respect to our product candidates the company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the company if at all the successful implementation of the company’s research and development programs and collaborations the success of the company’s license agreements the acceptance by the market of the company’s product candidates if approved and other factors including general economic conditions and regulatory developments not within the company’s control the factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements the forwardlooking statements are made only as of the date of this press release and the company undertakes no obligation to publicly update such forwardlooking statements to reflect subsequent events or circumstance axsome contact mark jacobson vice president operations axsome therapeutics inc  broadway th floor new york ny  tel  email wwwaxsomecom related articles other press releases by axsome therapeutics inc axsome therapeutics initiates phase  trial of axs for alzheimer’s disease agitation july    axsome therapeutics appoints john golubieski as chief financial officer july    axsome therapeutics appoints myrtle potter to its board of directors june    axsome therapeutics reports first quarter  financial results may    axsome therapeutics receives fda fast track designation for axs for alzheimer’s disease agitation may     other news releases in product  services announcement in the last  days profile axsome therapeutics inc   subscribe via rss  subscribe via atom  javascript new york new york united states   httpaxsomecom contact data axsome contact mark jacobson vice president operations axsome therapeutics inc  broadway th floor new york ny  tel  email wwwaxsomecom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files axsome therapeutics inc logo logo url  copy the link below formats available original medium small tags axs biotechnology axsome osteoarthritis rheumatoid arthritis newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved briefaxsome therapeutics announces axs meets primary endpoint in phase  clinical trial  business insider reuters bi intelligence events trending tech insider finance politics strategy life sports video all × from to you have successfully emailed the post × briefaxsome therapeutics announces axs meets primary endpoint in phase  clinical trial reuters jul    am  facebook linkedin twitter email print july  reuters  axsome therapeutics inc  axsome therapeutics announces axs moseic meloxicam and esomeprazole meets primary endpoint in phase  clinical trial  axsome therapeutics inc  ‍primary endpoint met with  times faster time to maximum plasma concentration tmax of meloxicam versus mobic​  says ‍received from us fda preind written guidance on a proposed clinical developmental plan for axs​  says ‍believes that axs is phase ready​  axsome therapeutics‍look forward to further development of axs and to a data readout for axs in complex regional pain syndrome anticipated in q​  axsome therapeutics inc  ‍axs was well tolerated with reported adverse events being similar across three treatment arms​  says ‍there were no serious adverse events in study​ source text for eikon further company coverage read the original article on reuters copyright  follow reuters on twitter more reuters company news briefaxsome therapeutics announces axs meets primary endpoin facebook linkedin twitter email print × recommended for you powered by sailthru briefaxsome therapeutics announces axs meets primary endpoint in phase  clinical trial briefaxsome therapeutics announces axs meets primary endpoint in phase  clinical trial july  reuters  axsome therapeutics inc recommended for you disclaimer featured apple is lagging the market as iphone  woes mount more the bottom line » heres how much you need to save for college every year depending on when you start more year by year » reuters emails  alerts get the best of business insider delivered to your inbox every day signup get the slide deck from henry blodgets ignition presentation on the future of digital     read business insider on the go available on ios or android find a job tech jobs clevel jobs media jobs design jobs finance jobs sales jobs see all jobs » thanks to our partners follow us on also check out  copyright   business insider inc all rights reserved registration on or use of this site constitutes acceptance of our terms of service and privacy policy disclaimer commerce policy made in nyc stock quotes by finanzennet international editions ukdeausinmysgplsenlfritjp axsome therapeutics overview  pipeline overview we aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated medicines that expand the treatment options available to caregivers and improve the lives of patients living with cns disorders axsome therapeutics inc is a clinicalstage biopharmaceutical company developing novel medicines for the management of central nervous system cns disorders by focusing on this therapeutic area we are addressing significant and growing markets where current treatment options are limited or inadequate our pipeline includes two latestage product candidates axs and axs which we are developing for multiple indications pipeline axsome therapeutics is building a portfolio of differentiated product candidates that address unmet medical needs some of our product candidates combine multiple mechanisms of action to produce novel medicines that address deficiencies of current approaches the company’s current pipeline includes two latestage product candidates and one preclinical candidate axs axs is a novel oral investigational drug product under development for the treatment of central nervous system cns disorders axs utilizes axsome’s technology of combining bupropion and dextromethorphan dextromethorphan is an nmda receptor antagonist sigma receptor agonist and inhibitor of the serotonin and norepinephrine transporters bupropion serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor and a nicotinic acetylcholine receptor antagonist we are initially developing axs for the treatment of the following conditions treatment resistant depression trd and agitation in patients with alzheimer’s disease ad axs is an investigational drug product not approved by the fdalearn more about axs and our target indications axs axs disodium zoledronate tetrahydrate is a potentially first in class oral targeted non opioid therapeutic for chronic pain we are initially developing axs for the treatment of pain in the following three conditions complex regional pain syndrome crps knee osteoarthritis oa associated with bone marrow lesions bmls and chronic low back pain clbp associated with modic changes mcs axs has been granted fast track designation by the fda for the treatment of pain associated with crps as well as for the treatment of knee oa associated with bmls axs has also been granted orphan drug designation by the fda and orphan medicinal product designation by the ema for the treatment of crps axs is an investigational product candidate not approved by the fdalearn more about axs and our target indications axsome therapeutics inc nasdaqaxsm axsome therapeutics inc axsm product news news  stocknewscom     follow us stocktwits twitter axsome therapeutics inc axsm product news news axsm – reports positive topline clinical trial results from a phase  pharmacokinetic study of axs a novel oral nonopioid fixeddose combination of meloxicam and esomeprazole being developed for the treatment of osteoarthritis and rheumatoid arthritis jul    am  by stocknewscom staff product news key facts surrounding this news item axsm had a powr rating of c neutral coming into today axsm was  below its day moving average coming into today axsm was  above its day moving average coming into today axsm was  above its day moving average coming into today axsm was  above its day moving average coming into today axsm was  above its day moving average coming into today axsm had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about axsome therapeutics inc axsm axsome therapeutics inc focuses on developing therapies for the management of pain neurological disorders and other central nervous system the company was founded in  and is based in new york city new york view our full axsm ticker page with ratings news and more axsm at a glance axsm current powr rating™ overall powr rating™ axsm current price   more axsm ratings data and news axsm price reaction the day of this event jul  axsm closing price axsm volume from avgleading up to this eventaxsm mo returnna axsm price chart more axsome therapeutics inc axsm news view all eventdate symbol news detail start price end price change powr rating loading please wait view all axsm news page generated in  seconds axsm key statistics  axsome therapeutics inc financial ratios  marketwatch bulletin att shares gain  in premarket as telecom surprises with q wireless result » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close axsome therapeutics inc nasdaq axsm go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus axsome therapeutics inc before the bell  quotes are delayed by  min jul    am axsm quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description axsome therapeutics inc is a clinical stage biopharmaceutical company which engages in developing novel therapies for the management of central nervous system disorders its product candidates include axs and axs which are developing for multiple indications the company was founded by herr axsome therapeutics inc is a clinical stage biopharmaceutical company which engages in developing novel therapies for the management of central nervous system disorders its product candidates include axs and axs which are developing for multiple indications the company was founded by herriot tabuteau on january   and is headquartered in new york ny valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  total debt to enterprise value  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr herriott tabuteau   chairman  chief executive officer mr mark l jacobson   secretary  vice presidentoperations ms constance ames   principal financial officer  treasurer ms myrtle s potter   director dr robert niecestro   vice presidentclinical  regulatory insider actions – purchase – sale  – number of transactions  date name shares transaction value  roger a jeffs director    derivativenonderivative trans at  per share   roger a jeffs director    derivativenonderivative trans at  per share   randall e kaye chief medical officer    acquisition at  per share   herriott tabuteau chief executive officer director    derivativenonderivative trans at  per share   mark coleman director    derivativenonderivative trans at  per share   mark coleman director    derivativenonderivative trans at  per share   mark coleman director    derivativenonderivative trans at  per share   roger a jeffs director    derivativenonderivative trans at  per share   randall e kaye chief medical officer    derivativenonderivative trans at  per share   constance ames vice president finance    derivativenonderivative trans at  per share   mark e saad director    derivativenonderivative trans at  per share  newslatestcompanyusaxsm marketwatch news on axsm no news currently available for axsm newsnonmarketwatchcompanyusaxsm other news on axsm will axsome therapeutics axsm continue to surge higher  am june    zackscom stocks to watch next week  am june    seeking alpha an analysis of axsome therapeutics upcoming catalysts  am may    seeking alpha biotech forum daily digest citron targets exact sciences spotlight on axsome therapeutics  am may    seeking alpha premarket gainers as of  am  am may    seeking alpha axsome therapeutics lands fda fast track designation for alzheimer’s treatment  am may    seeking alpha biopharma hit the bottom expectations are high for this year  pm april    seeking alpha axsome therapeutics axsm presents at th annual roth conference  am march    seeking alpha k axsome therapeutics inc  pm march    edgar online  edg  q k axsome therapeutics axsm investor presentation  slideshow  am feb    seeking alpha axsome therapeutics on go to start phase  study of axs in h  pm jan    seeking alpha grünenthal acquires thar pharmaceuticals during ipo process  pm nov    seeking alpha biggest movers in manufacturing stocks now – crbp crds ebio mtl  am nov    investorplacecom hottest manufacturing stocks now – avxs oiim afmd brcd  pm nov    investorplacecom biggest movers in manufacturing stocks now – vrx osn agle sgen  pm nov    investorplacecom healthcare ratings roundup  new coverage  am oct    seeking alpha biotech forum daily digest will medivation ignite takeover wave is acadia next valeants saga continues  am aug    seeking alpha hottest manufacturing stocks now – hsgx cbay pti evok  pm aug    investorplacecom qa axsome therapeutics inc  pm aug    edgar online  edg  q k q axsome therapeutics inc  pm aug    edgar online  edg  q k loading more headlines at a glance axsome therapeutics inc  broadway th floor new york new york  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for axsm newspressreleasecompanyusaxsm press releases on axsm axsome therapeutics announces axs moseictm meloxicam and esomeprazole meets primary endpoint in phase  clinical trial  am july    globenewswire axsome therapeutics initiates phase  trial of axs for alzheimers disease agitation  am july    globenewswire axsome therapeutics appoints john golubieski as chief financial officer  am july    globenewswire axsome therapeutics appoints myrtle potter to its board of directors  am june    globenewswire blog coverage axsome received fast track designation for its treatment of agitation in patients with alzheimers disease  am may    accesswire axsome therapeutics reports first quarter  financial results  am may    globenewswire axsome therapeutics receives fda fast track designation for axs for alzheimers disease agitation  am may    globenewswire axsome therapeutics announces full exercise of underwriters option to purchase additional shares  am march    globenewswire axsome therapeutics to present at the th annual needham healthcare conference  am march    globenewswire axsome therapeutics announces pricing of its public offering of common stock  am march    globenewswire axsome therapeutics announces proposed public offering of common stock  pm march    globenewswire axsome therapeutics reports fourth quarter and full year  financial results and provides business update  pm march    globenewswire axsome therapeutics to present at the th annual roth conference  am feb    globenewswire axsome therapeutics receives fda fast track designation for axs for treatment resistant depression  am feb    globenewswire axsome therapeutics to present at the  rbc capital markets global healthcare conference  am feb    globenewswire axsome therapeutics to present at the  bio ceo  investor conference  am feb    globenewswire axsome therapeutics to present at biotech showcase   am jan    globenewswire axsome therapeutics receives fda clearance of ind for phase  trial of axs in alzheimers disease agitation  am jan    globenewswire axsome therapeutics reports third quarter  financial results  pm nov    globenewswire axsome therapeutics enters into  million term loan agreement with silicon valley bank  am nov    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest astate national to be acquired by markel in deal valuing the insurer at nearly  million achip stocks are cool again but reality is here asunedison wins final approval for bankruptcy exit acocacola tops earnings estimates after cost cuts aa money manager struggles with the social pressure for ‘more house’ aatt shares gain  in premarket after company surprises analyst with q wireless results aboeing raises guidance after profit beat abiogen shares surge  after upgrade to buy at goldman sachs amarkel to acquire stane national cos in  million cash deal achipotle says sick staffer spread norovirus causing  billion market cap loss arbb bancorp prices ipo at  a share anvidias stock climbs  in premarket trade aamds stock soars toward month high as analysts boost price targets after upbeat results acities to move to if you want to work in tech — not including san francisco abiogen shares surge  after goldman sachs upgrade abiogen upgraded to buy at goldman sachs on alzheimers drug underleveraged balance sheet athe allure of ‘damaged’ stocks as tech mania goes wild aall the signs silicon valley isn’t nearly as awesome as it thinks it is aupdate six flags shares dip  premarket after company misses profit revenue estimates apenske automotive raises quarterly dividend to  cents from  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  axsome therapeutics inc  axsm company news at ally invest quotes snapshot  axsmaxsome therapeutics inc axsmnasdaqset alertoptionsstreaming chartslast pricenasdaq previous close  last trade as of pm et nasdaq minute delayed bidask quotestodays changebid size ask size day low  highna  navolume ksellbuysnapshotchartsnewsoptionsearningsfundamentalsfinancialsinsiders axsome therapeutics initiates phase  trial of axs for alzheimers disease agitationback to axsm news share storyam et  globe newswirefirst patient enrolled in the advance study agitation reported in nearly  of patients with alzheimers disease fda fast track designation previously received for axs for alzheimers disease agitation second indication for axs in latestage clinical trials new york july   globe newswire  axsome therapeutics inc nasdaqaxsm a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders enrolled the first patient in the advance addressing dementia via agitationcentered evaluation  study a phase  trial evaluating the efficacy and safety of axs for the treatment of alzheimers disease ad agitation axs is a combination of dextromethorphan an nmda receptor antagonist sigma receptor agonist and serotonin and norepinephrine reuptake inhibitor and bupropion a norepinephrine and dopamine reuptake inhibitor which also increases the bioavailability of dextromethorphan agitation is one of the most distressing and difficulttotreat behavioral symptoms in patients with alzheimers disease said jeffrey cummings md scd professor of neurology and director of the center for neurodegeneration and translational neuroscience at the cleveland clinic lerner college of medicine it is common being reported in about half of patients is one of the primary reasons for early nursing home placement and is associated with increased mortality nmda receptor antagonism sigma receptor agonism and serotonin and norepinephrine reuptake inhibition may be relevant mechanisms in this condition new treatments are needed for agitation and progress in this area is a welcome advance agitation places a heavy burden on patients with alzheimers disease and their caregivers said marc agronin md vice president of behavioral health and clinical research at miami jewish health and affiliate associate professor of psychiatry and neurology at university of miami miller school of medicine unfortunately there is currently no fdaapproved medication for this condition the mechanisms of action of axs may hold promise in treating alzheimers agitation we look forward to learning more about axs and its potential to relieve the symptoms of agitation through the advance trial the initiation of the advance trial reflects axsomes continued commitment to developing treatments for serious cns disorders for which there are limited treatment options said herriot tabuteau md chief executive officer of axsome the unique pharmacology of axs lends itself to the potential treatment of a variety of cns disorders with the stride trial in treatment resistant depression also underway axs is now being evaluated in latestage clinical trials in two separate cns indications about the advance study advance addressing dementia via agitationcentered evaluation  is a phase  multicenter randomized doubleblind controlled trial to evaluate the efficacy and safety of axs in patients with agitation associated with alzheimers disease  approximately  patients will be randomized in a  ratio to receive axs bupropion or placebo for  weeks the primary efficacy measure is the cohenmansfield agitation inventory cmai this trial incorporates a planned interim analysis by an independent data monitoring committee to assess the assumptions used to determine the sample size of the trial about alzheimers disease ad agitation alzheimers disease ad is a progressive neurodegenerative disorder that manifests initially as forgetfulness advancing to severe cognitive impairment and memory loss it afflicts an estimated  million individuals in the united states a number that is anticipated to increase to approximately  million by  in addition to cognitive decline individuals diagnosed with ad typically experience behavioral and psychological symptoms including agitation which is reported in approximately  of patients agitation is characterized by emotional distress aggressive behaviors disruptive irritability and disinhibition agitation in patients with ad has been associated with increased caregiver burden decreased functioning earlier nursing home placement and increased mortality there are currently no therapies approved by the fda for the treatment of agitation in patients with ad about axs axs is a novel oral investigational drug product under development for the treatment of central nervous system cns disorders axs utilizes axsomes technology of combining bupropion and dextromethorphan dextromethorphan is an nmda receptor antagonist sigma receptor agonist and inhibitor of the serotonin and norepinephrine transporters bupropion serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor and a nicotinic acetylcholine receptor antagonist axs is an investigational drug product not approved by the fda about axsome therapeutics inc axsome therapeutics inc is a clinicalstage biopharmaceutical company developing novel therapies for the management of central nervous system cns disorders for which there are limited treatment options axsomes product candidate portfolio includes two latestage candidates axs and axs axs is currently in a phase  trial in treatment resistant depression trd and a phase  trial in agitation in patients with alzheimers disease ad axs is currently in phase  trials in complex regional pain syndrome crps and knee osteoarthritis oa associated with bone marrow lesions bmls with an additional phase  trial planned in chronic low back pain clbp associated with modic changes mcs axs and axs are investigational drug products not approved by the fda for more information please visit the company website at wwwaxsomecom the company may occasionally disseminate material nonpublic information on the company website forward looking statements certain matters discussed in this press release are forwardlooking statements we may in some cases use terms such as predicts believes potential continue estimates anticipates expects plans intends may could might will should or other words that convey uncertainty of future events or outcomes to identify these forwardlooking statements in particular the companys statements regarding trends and potential future results are examples of such forwardlooking statements the forwardlooking statements include risks and uncertainties including but not limited to the success timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates including statements regarding the timing of initiation interim analyses and completion of the trials the timing of and our ability to obtain and maintain us food and drug administration or other regulatory authority approval of or other action with respect to our product candidates the companys ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the company if at all the successful implementation of the companys research and development programs and collaborations the success of the companys license agreements the acceptance by the market of the companys product candidates if approved and other factors including general economic conditions and regulatory developments not within the companys control the factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements the forwardlooking statements are made only as of the date of this press release and the company undertakes no obligation to publicly update such forwardlooking statements to reflect subsequent events or circumstance axsome contact mark jacobson vice president operations axsome therapeutics inc  broadway th floor new york ny  tel  email mjacobsonaxsomecom wwwaxsomecom other top stories axsmauthor brings spiritual hope to the failing heartsarms v makes a splash in the americasworld high voltage capacitors market  opportunitiesimmunoprecise enters agreement to develop immuneconnatural patches of vermont introduces aromatherapy w most popular storiesaxsome therapeutics initiates phase  trial of axsaxsome therapeutics announces publication of researcaxsome therapeutics reports q eps  vs estaxsome therapeutics reports axs meets primary endaxsome therapeutics to present at the  bio ceo most popular keyword searchesspy enter symbol or name ddd fnma nflx twtr f gpro bac baba amd fb mjna znga jcp amzn tsla kkd goog aapl   axsome therapeutics inc  axsm  stock price today  zacks free gift for zackscom visitors axsm is  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more axsome therapeutics inc axsm delayed data from nsdq  usd     updated jul    pm et premarket     am et add to portfolio zacks rank hold          style scores d value  d growth  b momentum  d vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est na current qtr est na current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for axsm all zacks’ analyst reports news for axsm zacks news for axsm other news for axsm will axsome therapeutics axsm continue to surge higher am est zacks axsm what are zacks experts saying now zacks private portfolio services more zacks news for axsm axsome therapeutics announces axs moseic¿ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial am est globenewswire axsome therapeutics initiates phase  trial of axs for alzheimer¿s disease agitation am est globenewswire axsome therapeutics appoints john golubieski as chief financial officer am est globenewswire midday gainers  losers pm est seeking alpha axsome looks good on multiple catalysts fast track designation eases liquidity concerns am est talkmarkets more other news for axsm premium research for axsm zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores d value  d growth  b momentum  d vgm earnings esp  research report for axsm snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank axsome therapeutics inc axsm agenus inc agen bioverativ inc bivv enzo biochem inc enz exact sciences corporation exas exelixis inc exel vertex pharmaceuticals incorporated vrtx see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary axsome therapeutics inc is a biopharmaceutical company the company is focused on developing novel therapies for the management of pain and other central nervous system disorders its product candidate portfolio consists of axs and axs which are in clinical trial stage axsome therapeutics inc is based in new york axsome therapeutics k mar    pm  seeking alphasign in  join nowgo»axsome therapeutics axsmform k  current reportmar    pmabout axsome therapeutics axsmview as pdf axsome therapeutics inc form k received       united states securities and exchange commission washington dc    form k     current report pursuant to section  or d of the securities exchange act of    march   date of report date of earliest event reported   axsome therapeutics inc exact name of registrant as specified in its charter     delaware       state or other jurisdiction   commission   irs employer of incorporation   file number   identification no      broadway th floor     new york new york    address of principal executive offices   zip code   registrants telephone number including area code       former name or former address if changed since last report   check the appropriate box below if the form k is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   o             written communications pursuant to rule  under the securities act  cfr    o             soliciting material pursuant to rule a under the exchange act  cfr a   o             precommencement communications pursuant to rule db under the exchange act  cfr db   o             precommencement communications pursuant to rule ec under the exchange act  cfr ec         item  other events   on march   axsome therapeutics inc the company updated its presentation slide deck in preparation for a presentation by herriot tabuteau md chief executive officer of the company at the th annual needham healthcare conference the conference on april   dr tabuteau will be presenting at the conference to provide an overview of the companys business and latestage clinical product candidates axs and axs   included in the new corporate slide deck is updated financial guidance from the company in connection with its previously disclosed march  public offering of common stock the offering the company now believes that with the net proceeds from the offering together with previously existing cash it will have sufficient funds to meet its anticipated operating cash requirements into the first quarter of  the company has based this estimate on assumptions that may prove to be wrong and it could spend its available financial resources faster than it currently expects   attached as exhibit  to this current report on form k is a copy of the presentation slide deck to be used in connection with the planned presentation   item  financial statements and exhibits   d            exhibits   exhibit       number   description      corporate presentation        signatures   pursuant to the requirements of the securities exchange act of  the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized     axsome therapeutics inc             dated march   by s herriot tabuteau md   name herriot tabuteau md   title chief executive officer    exhibit  nasdaq axsm april    axsome therapeutics inc click to enlarge   fls forwardlooking statements  safe harbor certain information contained in this presentation may include forwardlooking statements within the meani ng of the pri vate securities litigation reform act of  we may in some cases use terms such as predicts believes potential conti nue estimates anticipates expects plans intends may could might will should or other words that convey uncertainty of future events or outcomes to identify these forwardlooking statements in particular the companys statements regarding trends and potential future results are examples of such forwardlooking statements the forwardlooking statements include risks and uncertai nties includi ng but not limited to the success timi ng and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates including statements regarding the timing of initiation and completion of the trials interim analyses and receipt of interim results the timing of and our ability to obtai n and maintain us food and drug administration or other regulatory authority approval of or other action with respect to our product candidates the companys ability to obtain additional capital necessary to fund its operations the companys ability to generate revenues in the future the companys ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the company if at all the successful implementation of the companys research and development programs the enforceability of the companys license agreements the acceptance by the market of the companys product candidates if approved and other factors i ncluding general economic conditions and regulatory developments not withi n the companys control these factors could cause actual results and developments to be materially different from those expressed in or implied by such statements forwardlooking statements are not guarantees of future performance and actual results may differ materially from those projected  the forwardlooking statements are made only as of the date of this presentation and the company undertakes no obligation to publicly update such forwardlooking statements to reflect subsequent events or circumstance this presentation also contains estimates and other statistical data made by i ndependent parties and by us relating to market size and other data about our i ndustry this data i nvolves a number of assumptions and limitations and you are cautioned not to give undue weight to such estimates neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation in addition these projections assumptions and estimates are necessarily subject to a high degree of uncertainty and risk  axsome therapeutics inc  click to enlarge   axsome is addressing growing markets where current treatment options are limited or inadequate by leveraging wellcharacterized compounds to create nov el therapeutics to meet unmet medical needs and improve the lives of patients  axsome therapeutics inc  click to enlarge   overview our candidates and pipeline  two differentiated phase stage assets targeting significant and growing markets  axs novel therapeutic combination with multiple mechanisms for cns disorders  axs oral nonopioid longacting potentially firstinclass therapeutic for chronic pain  results from all  ongoing phase  trials expected over the next  novel indications positive proofs of concept  patent protection to   months  worldwide rights ant depression fast t imers disease orphan designation fast track granted abbreviations  bup  bupropion dm  dextrom ethorphan crps  com plex regional pain syndrom e oa  os teoarthritis  bml  bone marrow les ions spa  special protocol as s es sment clbp  chronic low back pain mc  modic changes   axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs dm  bup treatment resist agitation in alzhe rack granted initiated axs disodium zoledronate tetrahydrate crps us  eu knee oa with bml clbp with mcs s spa received fast track granted initiated initiated axs pain click to enlarge    axsome therapeutics inc  axs dextromethorphan dm  bupropion bup novel therapy for cns disorders  treatment resistant depression trd  agitation in alzheimers disease ad click to enlarge   axs cns disorders mechanisms of action pharmacodynamic synergy relevant indications related agents   ketamine memantine namenda®   fluvoxamine luvox® donepezil aricept®   duloxetine cymbalta® venlafaxine effexor®    escitalopram lexapro® fluoxetine prozac® sertraline zoloft®  bupropion wellbutrin®  bupropion wellbutrin® dm  dextrom ethorphan bup  bupropion relevant pres ent  axsome therapeutics inc  mechanism of action dm bup axs dmbup nmda receptor antagonist sigmar agonist norepinephrine reuptake inhibitor serotonin reuptake inhibitor dopamine reuptake inhibitor nicotinic ach receptor antagonist click to enlarge   axs cns disorders mechanisms of actionand relevant indications pharmacodynamic synergy relevant indications related agents  memantine namenda®  donepezil aricept®  venlafaxine effexor® dm  dextrom ethorphan bup  bupropion relevant pres ent  indications listed are associated w ith the mechanism of action and are not related to either dm or bup unless specif ically noted  agents do not contain dm or bup unless specif ically noted  axsome therapeutics inc   ketamine  fluvoxamine luvox®  duloxetine cymbalta®  escitalopram lexapro®  fluoxetine prozac®  sertraline zoloft®  bupropion wellbutrin®  bupropion wellbutrin® mechanism of action dm bup axs dmbup nmda receptor antagonist sigmar agonist norepinephrine reuptake inhibitor serotonin reuptake inhibitor dopamine reuptake inhibitor nicotinic ach receptor antagonist click to enlarge   axs cns disorders novel therapy for cns disorders dm alone dxo difficult to achieve potential therapeutic plasma levels dm dm rapid metabolism axs dm  bup dxo inhibits dm metabolism  pharmacokinetic synergy  potential pharmacodynamic dm bup dm bup synergy  potential efficacy in cns disorders dm concentration increased to therapeutic range dm  dextrom ethorphan dxo  dextrorphan bup  bupropion bup active at cns receptors  phase  trials with axs completed  significant increase in dm plasma levels  phase  in trd initiated  axsome therapeutics inc  ip overview   issued patents  protection through  click to enlarge   axs cns ph  disorders results dextromethorphan auc dextromethorphan cm ax p p       dm  mg dm  mg  bup  mg axs dm  mg dm  mg  bup  mg axs axsome data on f ile dm dextromethorphan bup bupropion  axsome therapeutics inc  auc nghrml cmax ngml     click to enlarge   axs cns ph  disorders results dextromethorphan auc dextromethorphan cm ax p p       dm  mg dm  mg  bup  mg axs dm  mg dm  mg  bup  mg axs dose auc nghrml dose cm ax ngml dm  mg  q  mg dm  mg  q  mg   dm  mg  q  mg dm  mg  q  mg   axsome data on f ile  nuedexta® nda  fda clinical pharmacology review  dm dextromethorphan q quinidine bup bupropion  axsome therapeutics inc  auc nghrml cmax ngml     click to enlarge   axs cns disorders trd overview  major depressive disorder mdd is a leading cause of disease burden in the us   and  of mdd patients have inadequate response to initial therapy and second line therapy respectively  only  approved drug for trd  unmet medical need  axs combines the moa of  distinct antidepressant drug classes into one novel oral therapeutic m patients the us in  dm antidepressant effects demonstrated preclinically clinically  phase  ongoing and nt depression  marcus sc olf son m arch gen psychiatry   rush aj et al am j psychiatry   us census bureau population april   to july    mathers cd plos med   e  axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs treatment resista initiated click to enlarge   axs cns disorders trd clinical rationale  dm and metabolic inhibitor reduce depressive symptoms in trd and in ad depressive symptom reduction in ad agitation patients treated with dm and metabolic inhibitor dmq symptom reduction in trd patients treated with dm and metabolic inhibitor placebo  mg          wk  wk  wk  wk  wk  wk  time weeks  failed  to  prior treatments   of patients had ≥  reduction in madrs  p versus baseline  p  murrough et al acnp  poster presentation manuscript under review   cummings j et al jama   axsome therapeutics inc  change in montgomeryasberg depression rating madrs scale change in cornell scale score    dmq titration dmq  mg q  hrs click to enlarge   axs cns disorders trd phase  design a phase  trial to assess the efficacy and safety of axs in the treatment of trd  randomization of inadequate responders period  doubleblind  weeks period  openlabel  weeks n bup  dm bup  bupropion dm  dextrom ethorphan  primary endpoint change in depression score from randomization to end of study measured using the montgomeryas berg depression rating scale madrs  key inclusion criteria  male or female  years old  history of inadequate response to  or  adequate antidepressant treatments  axsome therapeutics inc  bupropion arm b n bupropion axs arm a n click to enlarge   axs cns disorders agitationin ad overview  agitation and aggression seen in approximately  of ad patients during year period  characterized by emotional distress aggressive behaviors disruptive irritability disinhibition and  associated with caregiver burden m patients    accelerated cognitive decline earlier nursing home placement increased mortality the us in  no approved medication  unmet medical need  proof of concept dm plus metabolic inhibitor reduced in ad patients  fda clearance received for ind for phase  trial agitation imers disease  ryu sh et al am j geriatr psychiatry   hebert le et al neurology   steinberg m et al int j geriatr psychiatry   antonsdottir im et al expert opin pharmacother   rabins pv et al alzheimers dement    axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs agitation in alzhe click to enlarge   axs cns disorders agitationin ad clinical rationale change in agitationaggression scores in ad with dm and metabolic inhibitor quinidine q  randomized doubleblind placebocontrolled twostage trial  placebo n  mg dm   mg quinidine q n for stage   dmq treatment reduced agitation aggression in ad by  vs  for placebo pprimary endpoint  statistically significant improvement in multiple secondary endpoints  dm plasma levels achieved with axs target therapeutic range placebo dmq    in   potential for additional contribution bupropion component of axs from  cummings j et al jama   axsome therapeutics inc  change in npi agitationaggression domain p click to enlarge   axs cns disorders agitation in ad phase  design a phase  trial to assess the efficacy and safety of axs in the treatment of agitation in ad screening doubleblind phase bup  dm n  randomization bup  bupropion dm  dextrom ethorphan  primary endpoint cohenmansfield  key inclusion criteria agitation inventory cmai  diagnosis of probable alzheimers disease  clinically significant agitation  axsome therapeutics inc  placebo bupropion axs arm a n arm b n arm c n click to enlarge    axsome therapeutics inc  s disodium zoledronate tetrahydrate novel therapy for chronic pain  complex regional pain syndrome crps  knee osteoarthritis oa with bone marrow lesions bmls  chronic low back pain clbp with modic changes mcs crps image source voet c et al freseach  click to enlarge   axs chronic pain differentiated therapy axs disodium zoledronate tetrahydrate oral dose longacting targeted therapy nonopioid nov el mechanism claims cover axs and related substances and disease indications  axsome therapeutics inc  ip overview   issued patents  protection through   drug delivery pharmacokinetic composition of matter and method of use claims  us orphan drug designation  years exclusivity  eu orphan medicinal product designation  years exclusivity  years with pip click to enlarge   axs chronic pain therapy via multiple mechanisms of action axs disodium zoledronate tetrahydrate inhibits boneresorbing osteoclasts downregulates acidsensing ion channels reduces proinflammatory cytokine production antiangiogenic ▼tnfα production ▼il production ▼il production ▼angiogenesis ▼cfos expression ▼decreased bone resorption ▼farnesyl pyrophosphate synthase fpps ▼asica expression ▼asic activation ▼trpv activation  acid is a w ell know n cause of pain  green jr rogers mj drug dev res   nagae m et al bone   abe y et al j bone miner metab    wolf am et al haematologica   derenne s et al bone miner res   stathopoulos gt et al am j respir crit care med   misso g et al cancer biol ther    axsome therapeutics inc click to enlarge   axs chronic pain lead indications and market potential case  capello zj et al j hand surg am   krämer hh et al pain   parkitny l et al neurology   moseley gl et al j pain   driban jb et al arthritis res ther r  hunter dj et al arthritis res ther r  kazakia gj et al osteoarthritis cartilage   zhang y et al eur spine j   järvinen j et al spine issls society meeting ab stracts oct vol suppl abstract gp  rahme r moussa r am j neuroradiol   law rence rc et al arthritis rheum   zhang y jordan jm clin geriatr med   tanamas sk et al rheumatology   guermazi a et al bmj e  jensen ok et al spine j feb  piis  us census bureau population april   to july    axsome therapeutics inc  complex regional pain syndrome crps  localized bone resorption  increased proinflammatory cytokines  new s per year in the us knee osteoarthritis oa with bone marrow lesions bmls  bmls are associated with pain in knee oa  bmls increased bone turnover decreased bone mineral density m patients in the us chronic low back pain clbp with modic changes mcs  mcs are associated with low back pain  mcs increased bone turnover proinflammatory cytokines vascular density m patients in the us click to enlarge   axs chronic pain phase  results and oral preference time days  phase  summary  oral administration of axs resulted in rapid absorption of zoledronic acid  significant plasma levels attained  robust pharmacodynamics pd effects  pd relevant to targeted pain indications  axs was well tolerated        patientstated preference for oral vs iv  assessed in  patients treated  years with oral or iv bisphosphonates  oral clodronate or ibandronate daily  iv zoledronic acid monthly then every  months  oral preference at randomization and therapy completion   respectively  potential safety advantage      iv preference oral preference  gralow  et al j clin oncol   suppl abstr   gralow  et al j clin oncol   suppl abstr   axsome therapeutics inc  change in osteoclast activity serum ctx patient preference   zoledronic acid iv mg axs oral tablet dose a axs oral tablet dose b axs oral tablet dose c click to enlarge   axs chronic pain crps overview  severe continuous disabling pain in a limb  sensation described as burning stabbing throbbing  localized bone resorption increased proinflammatory cytokines  common pain meds eg nsaids opioids gabapentin are considered ineffective  no approved drug  high unmet need  phase  ongoing bone scan hands  grinding orphan disease new  cases per year in the us  issued us patents protection into   uses of oral zoledronic acid for crps orphan designation fast track granted  goebel a complex regional pain syndrome in adult rheumatology oxford  by permission of oxf ord university press  sampath s et al indian j nucl medjanmar  capello zj et al j hand surg am   krämer hh et al pain   parkitny l et al neurology   bruehl s anesthesiology   moseley gl et al j pain   axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs crps us  eu initiated click to enlarge   axs chronic pain crps preclinical and clinical rationale preclinical  well validated crps model replicates inciting trauma clinical presentation natural history and pathologic changes  oral administration of axs significant pain and edema reduction improved clinical  clinical trials  randomized doubleblind placebocontrolled trials with  different bisphosphonates  pain reduction mean  reduction in vas pain scores range  to  during doubleblind phases  statistical significance p p p p p weight bearing axs effect in crps model p           potency of bisphosphonates potency of axs  to   adami s et al ann rheum dis   varenna m et al j rheumatol   robinson jn et al pain med   manicourt dh et al arthritis rheum   varenna m et al rheumatology oxford   green jr rogers mj drug dev res  pain edema weight bearing  axsome therapeutics inc   change vs placebo p p click to enlarge   axs chronic pain crps phase  design a phase  trial to assess the efficacy and safety of axs in the treatment of pain associated with crps type  crps treatment evaluation  study screening baseline doubleblind phase  weeks disodium zoledronate tetrahydrate n  randomization  week followup  primary endpoint change in pain intensity from baseline to week  measured using the  numerical rating scale nrs  key inclusion criteria  male or female ≥ years old recently diagnosed with crps type   average nrs pain intensity score of ≥  dosage once per week for six weeks no drug for last six weeks  interim analysis when half of patients have completed doubleblind phase  axsome therapeutics inc  placebo arm b n axs arm a n click to enlarge   axs chronic pain knee oa with bmls overview  bone marrow lesions bmls on mri are associated with pain in knee osteoarthritis oa mri knee side view  bmls are regions of increased mineral density bone turnover and reduced femur a p  zoledronic acid inhibits density bone resorption and increases mineral  phase  results zoledronic acid reduced pain and bml size in patients with knee osteoarthritis  phase  being conducted under special protocol assessment spa  issued us patents protection into   uses of zoledronic acid for knee pain bml tibia m patients in the us  mri show ing bml in medial tibia f rom driban et al arthritis res ther r  driban jb et al arthritis res ther r  hunter dj et al arthritis res ther r  kazakia gj et al osteoarthritis cartilage   law rence rc et al arthritis rheum   zhang y jordan jm clin geriatr med   tanamas sk et al rheumatology   guermazi a et al bmj e  jensen ok et al spine j feb  piis  us census bureau population april   to july    axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs knee oa with bml s spa received fast track granted initiated click to enlarge   axs chronic pain knee oa with bmls phase  results change in pain intensity at  mos change in bml size at  mos bml at baseline and post zoledronic acid treatment placebo zoledronic acid placebo zoledronic acid   baseline      months post treatment  randomized doubleblind placebocontrolled trial n  placebo n zoledronic acid iv n  primary endpoints  pain intensity measured using mm vas  bml size on mri laslett ll et al ann rheum dis  mri images courtesy of prof  graeme jones  axsome therapeutics inc  vas change bml area mm change   p   p click to enlarge   axs chronic pain knee oa with bmls phase  design a phase  trial to assess the efficacy and safety of axs in the treatment of pain of knee oa associated with bmls clinical knee oa symptom treatment  study screening baseline doubleblind phase  weeks special prot ocol a ssessment spa  receiv ed n  randomization  primary endpoint change in pain intensity from baseline to week  measured using the  numerical rating scale nrs  key inclusion criteria  male at least  years of age or postmenopausal female with knee oa and bmls  moderate or worse knee pain  dosage once per week for six weeks no drug for remainder of doubleblind phase  interim analysis to be performed on the first approximately  subjects enrolled  axsome therapeutics inc  placebo arm b n axs disodium zoledronate tetrahydrate arm a n click to enlarge   axs chronic pain clbp with mcs overview  modic changes mcs type  m on mri are associated with chronic low back pain clbp  increased bone turnover on bone scan is seen in m lesions  increased proinflammatory cytokines and vascular density seen in m lesions  zoledronic acid reduces bone turnover suppresses the production of inflammatory mediators and is antiangiogenic  phase  results zoledronic acid reduced pain in patients with clbp mri lumbar side view m a p disc m patients in the us  fda clearance received for ind for phase contingent upon resources  trial  initiation  issued us patents protection into   uses of oral zoledronic acid for low back pain  mri show ing modic type  lesions f rom luoma k et al european congress of radiology ecr poster b  zhang y et al eur spine j   järvinen j et al spine issls society meeting ab stracts oct volume suppl abstract gp  rahme r moussa r am j neuroradiol   law rence rc et al arthritis rheum   zhang y jordan jm clin geriatr med   jensen ok et al spine j feb  piis  us census bureau population april   to july    axsome therapeutics inc  product candidate preclinical phase  phase  phase  axs clbp with mcs click to enlarge   axs chronic pain clbp with mcs phase  results change in pain intensity at  month nsaid use at one year  placebo zoledronic acid        placebo zoledronic acid   randomized doubleblind placebocontrolled trial n  placebo n zoledronic acid iv n  primary endpoint pain intensity measured using cm vas axsome data on f ile  axsome therapeutics inc  vas change  of patients using nsaids   p p   click to enlarge   corporate barriers to entry  issued us patents  under review  issued ous patent claims extending to   pending  issued us patents claims extending to   pending proprietary manufacturing drug product formulation proprietary manufacturing api synthesis eu orphan medicinal product designation  yrs exclusivity  yrs with pip axs axs us orphan drug designation  yrs exclusivity claim s cover axs and related s ubs tances and dis ease indications  axsome therapeutics inc  click to enlarge   corporate our team group at ubs diplomat of the american board of  axsome therapeutics inc  management herriot tabuteau md founder  ceo robert niecestro phd vp clinical  regulatory connie ames cpa vp finance mark jacobson ma vp operations board of directors roger jeffs phd former president coceo director united therapeutics corp prior positions at amgen and burroughs wellcome mark saad former cfo bird rock bio inc former coo of the global healthcare mark coleman md medical director national spine and pain centers anesthesiology herriot tabuteau md chairman click to enlarge   corporate key financial information cash  million debt outstanding  million common shares outstanding  million options and warrants outstanding  million  subsequent financing gross proceeds of approximately  million raised in march  common stock offering of  million shares  financial guidance recent financing extends estimated cash runway into the first quarter of   excludes debt dis count of  m illion  cons is ts of  m illion options and  m illion warrants   axsome therapeutics inc  as of december   click to enlarge   overview anticipated nearterm clinical milestones abbreviations  ad  alzheim ers dis ease bup  bupropion clbp  chronic low back pain crps  com plex regional pain syndrom e dm  dextrom ethorphan oa  os teoarthritis  trd  treatm ent res is tant depres sion ✔ accom plis hed m ilestone  upcom ing m ilestone  axsome therapeutics inc  product candidate indication h  h  h  axs dm  bup trd ✔ fast track designation  stride topline results q ad agitation ✔ ph  ind fda clearance  ph  trial start q axs disodium zoledronate tetrahydrate crps  create interim efficacy analysis readout q knee oa  coast interim analysis readout q clbp ✔ ph  ind fda clearance click to enlarge   for more information please contact mark jacobson vp operations  mjacobsona xsomecom axsomecom click to enlarge   axsome therapeutics inc private company information  bloomberg july    am et pharmaceuticals company overview of axsome therapeutics inc snapshot people company overview axsome therapeutics inc a clinicalstage biopharmaceutical company develops therapies for the management of central nervous system cns disorders the company’s product candidates include axs that is in phase iii trial for the treatment of treatment resistant depression and alzheimer’s disease agitation and axs which is in phase iii trial to treat complex regional pain syndrome knee osteoarthritis related to bone marrow lesions and chronic low back pain related to modic changes it is also developing axs a preclinical product candidate for cns disorders including chronic pain the company was founded in  and is based in new york new york  broadwayth floornew york ny united statesfounded in  employees phone  fax  axsomecom key executives for axsome therapeutics inc dr herriot tabuteau md founder chairman ceo  president age  total annual compensation k ms constance ames vice president of finance and treasurer age  total annual compensation k dr randall e kaye md senior clinical advisor age  total annual compensation k compensation as of fiscal year  axsome therapeutics inc key developments axsome therapeutics inc initiates phase  trial of axs for alzheimer’s disease agitation jul   axsome therapeutics inc enrolled the first patient in the advance addressing dementia via agitationcentered evaluation  study a phase  trial evaluating the efficacy and safety of axs for the treatment of alzheimer’s disease ad agitation axs is a combination of dextromethorphan an nmda receptor antagonist sigma receptor agonist and serotonin and norepinephrine reuptake inhibitor and bupropion a norepinephrine and dopamine reuptake inhibitor which also increases the bioavailability of dextromethorphan advance addressing dementia via agitationcentered evaluation  is a phase  multicenter randomized doubleblind controlled trial to evaluate the efficacy and safety of axs in patients with agitation associated with alzheimer’s disease approximately  patients will be randomized in a  ratio to receive axs bupropion or placebo for  weeks the primary efficacy measure is the cohenmansfield agitation inventory cmai this trial incorporates a planned interim analysis by an independent data monitoring committee to assess the assumptions used to determine the sample size of the trial axsome therapeutics inc appoints john golubieski as chief financial officer effective august   jul   axsome therapeutics inc announced the appointment of john golubieski as chief financial officer effective august   prior to joining axsome mr golubieski was the chief financial officer of osmotica holdings axsome therapeutics inc appoints myrtle potter to its board of directors jun   axsome therapeutics inc announced the appointment of myrtle potter to its board of directors ms potter is the chief executive officer and founder of myrtle potter  company ms potter previously served as the president commercial operations and chief operating officer of genentech and held executive operating positions at bristolmyers squibb and merck ms potter currently serves on the board of directors of liberty mutual holding company rite aid corporation insmed and proteus digital health she is also on the board of trustees of the university of chicago and previously served on the boards of everyday health medco health solutions and amazoncom similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target private placement november    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact axsome therapeutics inc please visit axsomecom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close axsm stock price  news  axsome therapeutics inc  wall street journal dow jones a news corp company news corp is a network of leading companies in the worlds of diversified media news education and information services dow jones barrons bigcharts djx dow jones newswires factiva financial news mansion global marketwatch newsmart newsplus private markets risk  compliance wsjcom wsj pro wsj conference wsj video news corp big decisions business spectator checkout harper collins new york post proptiger rea realtorcom storyful the australian the sun the times djia futures ▲     sp  f ▲     stoxx  ▲     us  yr ▲  yield    crude oil ▲     euro ▲     subscribe now sign in the wall street journal us edition us asia europe india  china  japan july   todays paper sections my journal home world us politics economy business tech markets opinion arts life real estate todays paper show all sections hide all sections world home africa asia canada china europe latin america middle east economy world video us home economy law new york politics real time economics washington wire journal report us video whats news podcast politics home washington wire politics video wsjnbc news poll economy home real time economics economic forecasting survey economy video business home management techwsjd aerospace  defense autos  transportation commercial real estate consumer products energy entrepreneurship financial services food  services health care hospitality law manufacturing media  marketing natural resources retail cfo journal cio journal cmo today logistics report risk  compliance heard on the street business video journal report business podcast tech home cio journal geoffrey fowler christopher mims joanna stern li yuan billion dollar startup club tech video tech podcast startup stock trader markets home bonds commercial real estate commodities  futures currencies deals financial services funds stocks your money heard on the street moneybeat wealth adviser ahead of the tape cfo journal journal report market data markets video markets podcast moneybeat podcast watching your wealth podcast opinion home james freeman william a galston daniel henninger holman w jenkins william mcgurn peggy noonan mary anastasia ogrady jason riley kimberley a strassel books film television theater art masterpiece series music dance opera exhibition cultural commentary editorials commentary letters to the editor the weekend interview potomac watch podcast foreign edition podcast opinion video notable  quotable best of the web newsletter morning editorial report newsletter arts home books film television theater art masterpiece series arts video wsj magazine life home careers cars food  drink health ideas real estate science sports style  fashion travel life video wsj magazine wsj puzzles the future of everything real estate home commercial real estate house of the day mansion real estate video hide all sections aim higher reach further get the wall street journal  for  weeks subscribe now sign in reveal navigation options subscribe sign in axsome therapeutics inc axsm us nasdaq search view all companies at close  pm edt   usd   volume  pre market  am edt     pre market vol  volume   day avg vol   day range     week range        d  d  m  m ytd  y  y   advanced charting compare compare to benchmark djia sp  global dow nasdaq health carelife sciences compare to add open  prior close    day axsm  djia  russell k  health carelife sciences  overview overview profile financials income statement balance sheet cash flow research  ratings historical prices options advanced charting news axsome therapeutics incaxsm significant news only  press release axsome therapeutics announces axs moseictm meloxicam and esomeprazole meets primary endpoint in phase  clinical trial press release  dow jones newswires axsome therapeutics files k  other events dow jones newswires  press release axsome therapeutics initiates phase  trial of axs for alzheimers disease agitation press release  dow jones newswires axsome therapeutics files k  regulation fd dow jones newswires  dow jones newswires axsome therapeutics files k  changes exec mgmt dow jones newswires  press release axsome therapeutics appoints john golubieski as chief financial officer press release  dow jones newswires axsome therapeutics files k  changes exec mgmt dow jones newswires  dow jones newswires axsome therapeutics files k  regulation fd dow jones newswires  press release axsome therapeutics appoints myrtle potter to its board of directors press release  dow jones newswires axsome therapeutics files k  other events dow jones newswires  press release axsome therapeutics reports first quarter  financial results press release  press release axsome therapeutics receives fda fast track designation for axs for alzheimers disease agitation press release load more key stock data  pe ratio ttm the price to earnings pe ratio a key valuation measure is calculated by dividing the stocks most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing  month period earnings per share ttm a companys net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding market capitalization reflects the total market value of a company market cap is calculated by multiplying the number of shares outstanding by the stocks price for companies with multiple common share classes market capitalization includes both classes shares outstanding number of shares that are currently held by investors including restricted shares owned by the companys officers and insiders as well as those held by the public public float the number of shares in the hands of public investors and available to trade to calculate start with total shares outstanding and subtract the number of restricted shares restricted stock typically is that issued to company insiders with limits on when it may be traded dividend yield a companys dividend expressed as a percentage of its current stock price key stock data pe ratio ttm na eps ttm  market cap  m shares outstanding  m public float  m yield axsm has not issued dividends in more than  year latest dividend na exdividend date na  shares sold short the total number of shares of a security that have been sold short and not yet repurchased change from last percentage change in short interest from the previous report to the most recent report exchanges report short interest twice a month percent of float total short positions relative to the number of shares available to trade short interest  shares sold short  m change from last  percent of float   money flow uptickdowntick ratio money flow measures the relative buying and selling pressure on a stock based on the value of trades made on an uptick in price and the value of trades made on a downtick in price the updown ratio is calculated by dividing the value of uptick trades by the value of downtick trades net money flow is the value of uptick trades minus the value of downtick trades our calculations are based on comprehensive delayed quotes stock money flow na advertisement competitors axsm company change pe ttm pdli pdl biopharma inc    plpl plandai biotechnology inc    orpn bioblast pharma ltd    pirs pieris pharmaceuticals inc    more information on axsm competitor data provided by capital cube profile axsm axsome therapeutics inc is a clinical stage biopharmaceutical company which engages in developing novel therapies for the management of central nervous system disorders its product candidates include axs and axs which are developing for multiple indications  broadway new york new york  united states website map employees  sector pharmaceuticals sales or revenue  industry health carelife sciences y sales change  fiscal year ends december  download reports herriott tabuteau chairman  chief executive officer mark l jacobson secretary  vice presidentoperations constance ames principal financial officer  treasurer myrtle s potter director more research  ratings axsome therapeutics incaxsm pershare earnings actuals and estimates quarterly annual axsm will report fy  earnings on false axsm will report q earnings on false actual analyst range consensus     actual   actual   actual   actual     q q q q q q      actual      fy  fy  fy  fy  q  estimate trends current   month ago   months ago  q  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  more financials axsome therapeutics incaxsm quarterly annual net income   m mar  jun  sep  dec  mar    m     mar  quarter trend net income growth  sales or revenue  sales or revenue growth  ebitda  m  year trend net income growth  sales or revenue  sales or revenue growth  ebitda  m more overview notes  data providers realtime us stock quotes reflect trades reported through nasdaq only international stock quotes are delayed as per exchange requirements indexes may be realtime or delayed refer to time stamps on index quote pages for information on delay times quote data except us stocks provided by six financial information data is provided as is for informational purposes only and is not intended for trading purposes six financial information a does not make any express or implied warranties of any kind regarding the data including without limitation any warranty of merchantability or fitness for a particular purpose or use and b shall not be liable for any errors incompleteness interruption or delay action taken in reliance on any data or for any damages resulting therefrom data may be intentionally delayed pursuant to supplier requirements all of the mutual fund and etf information contained in this display was supplied by lipper a thomson reuters company subject to the following copyright  thomson reuters all rights reserved any copying republication or redistribution of lipper content including by caching framing or similar means is expressly prohibited without the prior written consent of lipper lipper shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon bond quotes are updated in realtime source tullett prebon currency quotes are updated in realtime source tullet prebon fundamental company data and analyst estimates provided by factset copyright factset research systems inc all rights reserved advertisement axsome therapeutics developing novel therapies for cns disorders expanding treatment options to improve the lives of patients living with cns disorders view pipeline axs treatment resistant depression trd trd occurs in individuals suffering from major depression who fail to respond to initial antidepressant treatments axs is a novel oral investigational drug product incorporating multiple mechanisms of action under development for the treatment of trd and alzheimer’s disease agitation learn more about trd and axs axs complex regional pain syndrome crps crps is characterized by excessive lingering pain in one of the limbs usually after an injury trauma or surgery axs is a novel oral nonopioid investigational drug product under development for the treatment of crps and other chronic pain conditions learn more about crps and axs in the news july   axsome therapeutics announces axs moseic™ meloxicam and esomeprazole meets primary endpoint in phase  clinical trial click to view full release july   axsome therapeutics initiates phase  trial of axs for alzheimer’s disease agitation click to view full release july   axsome therapeutics appoints john golubieski as chief financial officer click to view full release see all news knee oa clinical trialcoast study axs is being evaluated in the coast clinical knee osteoarthritis symptom treatment  coast is a phase  multinational multicenter randomized doubleblind placebocontrolled trial designed to evaluate the efficacy and safety of axs for the treatment of the pain of knee oa associated with bmls more information about the study can be found atwwwclinicaltrialsgovtrd clinical trialstride studytrdstudycomaxs is being evaluated in the stride symptom treatment in resistant depression  study stride is a phase  multicenter randomized doubleblind activecontrolled trial designed to evaluate the efficacy and safety of axs in the treatment of treatment resistant depression trd more information about the study can be found atwwwclinicaltrialsgovcrps clinical trialcreate trialcrpstrialcomaxs is being evaluated in the create crps treatment evaluation  study create is a phase  multinational multicenter randomized doubleblind placebocontrolled trial designed to evaluate the efficacy and safety of axs for the treatment of pain associated with complex regional pain syndrome crps more information about the study can be found atwwwclinicaltrialsgov bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one